A single biopsy can represent months of coordination, clinical decision-making and patient trust. In many areas of cancer and disease research, a small piece of tissue or bodily fluid may be the only opportunity to understand what is happening at the molecular level. Those are some high stakes.
On top of that, researchers are no longer just asking whether a mutation is present. They are asking how that mutation influences gene expression, how those changes alter protein activity and how those molecular shifts interact within broader biological systems. The stakes are even higher.
That tension – limited sample material alongside ever-expanding research questions – is reshaping how researchers approach sample preparation.
Here are three trends that are emerging.
1. More insight expected from every sample
Analytical technologies have advanced rapidly, and with them, expectations have risen. Researchers can now examine biology across multiple molecular layers in ways that were not possible a decade ago. With that capability comes a new assumption: each specimen should yield more than one dimension of insight.
Rather than dividing material across isolated workflows, laboratories are increasingly looking for ways to preserve molecular context and maximize what can be learned from a single sample. Multi-omics is an integrative research strategy that combines multiple “omics” disciplines, including genomic, transcriptomic and proteomic approaches, to provide a more comprehensive understanding of biological systems than any single analysis can achieve alone. By examining these molecular layers together, researchers can uncover the complex interactions and regulatory mechanisms that drive biological processes.
2. Multi-omics requires alignment, not just volume
Multi-omics is no longer about simply generating more data. It is about leveraging data that can be meaningfully connected.
When genomic, transcriptomic and proteomic analyses are performed independently, differences across datasets may reflect biology, workflow variation or both. As studies become more integrated, researchers are placing greater emphasis on maintaining alignment across molecular layers.
Deriving multiple analytes from the same biological input helps preserve that connection. The focus is shifting from parallel testing toward coordinated workflows that support more coherent interpretation. This coordination can enable a deeper understanding of biological processes by providing a comprehensive view of cellular mechanisms while also facilitating the identification of molecular signatures specific to a given disease or physiological state. This opens the door to research on personalized medicine, including the discovery of new biomarkers and precise drug targets.
3. Consistency starts at sample preparation
As research programs scale, reproducibility becomes increasingly important. Variability introduced during sample preparation can influence downstream results, particularly in studies working with limited material.
Structured, bead-based purification approaches and automated workflows are gaining attention because they offer a standardized framework for isolating proteins and nucleic acids. Automated workflows can especially help reduce manual labor demands and the risk of human error, as well as promote consistency and standardization across different sites and laboratories, enabling labs to more effectively scale research workflows. When protein, DNA and RNA purification steps are coordinated within a unified process, laboratories can support both scalability and consistency across analyses.
In multi-omics research, consistency at the beginning of the workflow helps strengthen confidence in results at the end.
Meeting the stakes
The reality and the beauty of scientific advancement is that the pursuit never stands still. It moves forward through partnership, with researchers pushing the boundaries of discovery and innovators developing the technologies that help them go further.
In the future, I expect we’ll see a continued shift from reacting to disease toward identifying risks earlier and intervening sooner. Early intervention depends on detecting subtle molecular changes before symptoms fully emerge. Those signals may begin at the level of gene expression or protein activity, not just DNA sequence alone.
As multi-omics approaches mature, the way we prepare samples will matter even more. Preserving biological continuity from the first step helps ensure that early molecular signals can be interpreted with confidence.
The stakes will always be high in cancer and disease research, but as our ambition and our capabilities rise together, I like our odds.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
